Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor

Study Type:	Interventional
Study Design:	Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment
Condition:	Gastrointestinal Stromal Tumor
Intervention:	Drug: regorafenib

  Participant Flow

  Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Participants were enrolled at three sites between February and December, 2010.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
Regorafenib	Regorafenib adminstered orally, 160 mg per day on days 1 through 21 of a 28 day cycle

Participant Flow:   Overall Study

	Regorafenib
STARTED	34
COMPLETED	33
NOT COMPLETED	1
Ineligible	1

  Baseline Characteristics

  Hide Baseline Characteristics

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Eligible patients were included in the baseline analysis population

Reporting Groups

	Description
Regorafenib	Regorafenib adminstered orally, 160 mg per day on days 1 through 21 of a 28 day cycle

Baseline Measures

	Regorafenib
Overall Participants Analyzed; [Units: Participants]	33
Age; [Units: Years]; Median (Full Range)	56; (25 to 76)
Sex: Female, Male; [Units: Participants]; Count of Participants
Female	14 42.4%
Male	19 57.6%
Region of Enrollment; [Units: Participants]
United States	33

  Outcome Measures

  Show All Outcome Measures

1. Primary:

Clinical Benefit as Defined by the Composite of Complete Response, Partial Response and Stable Disease Lasting 16 Weeks or More Per RECIST 1.1 as a Measure of Disease Control [ Time Frame: 2 years ]

  Show Outcome Measure 1

2. Secondary:

Progression-free Survival (PFS) [ Time Frame: From date of enrollment until date of first documented progression or date of death from any cause, whichever came first ]

  Hide Outcome Measure 2

Measure Type	Secondary
Measure Title	Progression-free Survival (PFS)
Measure Description	Progression-free survival is defined as the duration of time from start of study drug administration to time of objective disease progression or death due to any cause, whichever comes first. Progression is evaluated every 8 weeks using Response Criteria for Solid Tumors (RECIST) 1.1. Objective disease progression is defined as a 20% increase in the sum of the longest diameter of target lesion(s).
Time Frame	From date of enrollment until date of first documented progression or date of death from any cause, whichever came first

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups

	Description
Regorafenib	Regorafenib adminstered orally, 160 mg per day on days 1 through 21 of a 28 day cycle

Measured Values

	Regorafenib
Participants Analyzed	33
Progression-free Survival (PFS); [Units: Months]; Median (95% Confidence Interval)	10.0; (8.3 to 14.9)

No statistical analysis provided for Progression-free Survival (PFS)

  Serious Adverse Events

  Show Serious Adverse Events

  Other Adverse Events

  Show Other Adverse Events

  Limitations and Caveats

  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information

  Hide More Information

Certain Agreements:  

Principal Investigators are NOT employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:  

Name/Title: Dr. Suzanne George
Organization: Dana-Farber Cancer Institute
phone: 617-632-5204
e-mail: sgeorge2@partners.org

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Ben-Ami E, Barysauskas CM, von Mehren M, Heinrich MC, Corless CL, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Yap JT, Van den Abbeele AD, Solomon SM, Fletcher JA, Demetri GD, George S. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy. Ann Oncol. 2016 Sep;27(9):1794-9. doi: 10.1093/annonc/mdw228. Epub 2016 Jul 1.

Responsible Party:	Suzanne George, MD, Dana-Farber/Brigham and Women's Cancer Center
ClinicalTrials.gov Identifier:	NCT01068769 History of Changes
Other Study ID Numbers:	09-400
First Submitted:	February 12, 2010
First Posted:	February 15, 2010
Results First Submitted:	January 9, 2014
Results First Posted:	February 24, 2014
Last Update Posted:	March 1, 2018